Pelthos Therapeutics Inc.

PTHSReported to SECin USCIK 0001919246Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 6
Form 4 lines at Pelthos Therapeutics Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Friedberg Ezra M—Open-market sell$65624 sharesJul 7, 2026Friedberg Ezra M$656Sell · Jul 7Open-market sell24Jul 7, 2026
Friedberg Ezra M—Open-market sell$13,900534 sharesJul 7, 2026Friedberg Ezra M$13,900Sell · Jul 7Open-market sell534Jul 7, 2026
Pauls Matthew—Open-market sell$2,57294 sharesJul 7, 2026Pauls Matthew$2,572Sell · Jul 7Open-market sell94Jul 7, 2026
Pauls Matthew—Open-market sell$17,989692 sharesJul 7, 2026Pauls Matthew$17,989Sell · Jul 7Open-market sell692Jul 7, 2026
Greenleaf Peter—Open-market sell$2,31885 sharesJul 7, 2026Greenleaf Peter$2,318Sell · Jul 7Open-market sell85Jul 7, 2026